Post Traumatic Stress Disorder Ptsd Market

DelveInsight's "Post-Traumatic Stress Disorder (PTSD) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Post-Traumatic Stress Disorder (PTSD), historical and forecasted epidemiology as well as the Post-Traumatic Stress Disorder (PTSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Post-Traumatic Stress Disorder (PTSD) market report provides current treatment practices, emerging drugs, Post-Traumatic Stress Disorder (PTSD) market share of the individual therapies, current and forecasted Post-Traumatic Stress Disorder (PTSD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Post-Traumatic Stress Disorder (PTSD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Post-Traumatic Stress Disorder (PTSD) Understanding and Treatment Algorithm

Post-Traumatic Stress Disorder (PTSD) has been described as “the complex somatic, cognitive, affective, and behavioral effects of psychological trauma.” It is characterized by intrusive thoughts, nightmares, and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.

 

PTSD symptoms may start within 1 month of a traumatic event, but sometimes symptoms may not appear until years after the event. These symptoms cause significant problems in social or work situations and relationships. They can also interfere with the ability to go about the normal daily tasks, and the symptoms are generally grouped into four types: intrusive memories, avoidance, negative changes in thinking and mood, and changes in physical and emotional reactions. Symptoms can vary over time or vary from person to person. Patients can develop PTSD when they go through, see or learn about an event involving actual or threatened death, serious injury, or sexual violation. Several factors can play a role in how people respond to traumatic events. Genetics, for example, can influence how people handle stress during and after a trauma. People may be more likely to develop PTSD if they also have an existing mental health condition, have experienced trauma in the past, face other life stressors, and lack social support.

 

Diagnosis

PTSD is not diagnosed until at least one month has passed since the traumatic event happened. If symptoms of PTSD are present, the doctor will begin an evaluation by performing a complete medical history and physical exam. Although there are no lab tests to diagnose PTSD specifically, the doctor may use various tests to rule out physical illness as the cause of the symptoms. If no physical illness is found, one may be referred to a psychiatrist, psychologist, or other mental health professionals specially trained to diagnose and treat mental illnesses. Psychiatrists and psychologists use specially designed interview and assessment tools to evaluate a person for the presence of PTSD or other psychiatric conditions. The doctor bases their diagnosis of PTSD on reported symptoms, including any problems with functioning caused by the symptoms. The doctor then determines if the symptoms and degree of dysfunction indicate PTSD. PTSD is diagnosed if the person has symptoms of PTSD that last for more than 1 month.

Post-Traumatic Stress Disorder (PTSD) Epidemiology

The epidemiology section provides insights about the historical and current Post-Traumatic Stress Disorder (PTSD) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Post-Traumatic Stress Disorder (PTSD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

In the year 2021, the total diagnosed prevalent cases of Post-Traumatic Stress Disorder (PTSD) was 5,340,957 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

Country Wise- Post-Traumatic Stress Disorder (PTSD) Epidemiology

The epidemiology segment also provides the Post-Traumatic Stress Disorder (PTSD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Post-Traumatic Stress Disorder (PTSD) Drug Chapters

The drug chapter segment of the Post-Traumatic Stress Disorder (PTSD) report encloses the detailed analysis of Post-Traumatic Stress Disorder (PTSD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Post-Traumatic Stress Disorder (PTSD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Post-Traumatic Stress Disorder (PTSD) treatment.

Post-Traumatic Stress Disorder (PTSD) Market Outlook

The Post-Traumatic Stress Disorder (PTSD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Post-Traumatic Stress Disorder (PTSD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

 

This segment gives a thorough detail of Post-Traumatic Stress Disorder (PTSD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Post-Traumatic Stress Disorder (PTSD) market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

The Post-Traumatic Stress Disorder (PTSD) market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of Post-Traumatic Stress Disorder (PTSD) in the seven major markets is expected to increase during the study period (2019–2032). In 2021, the total market size of Post-Traumatic Stress Disorder (PTSD) was USD 1,740.2 million which is expected to rise during the study period (2019–2032).

 

The United States Market Outlook

The total market size of Post-Traumatic Stress Disorder (PTSD) in the United States accounted for USD 1,549.9 million in 2021 which is expected to rise during the study period (2019–2032).

 

EU-5 Countries: Market Outlook

In EU5, the total market size of Post-Traumatic Stress Disorder (PTSD) was USD 163.4 million in 2021, which is expected to rise during the study period (2019–2032).

 

Japan Market Outlook

In Japan, the total market size of Post-Traumatic Stress Disorder (PTSD) was USD 26.9 million in 2021, which is expected to rise during the study period (2019–2032).

Post-Traumatic Stress Disorder (PTSD) Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Post-Traumatic Stress Disorder (PTSD) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Post-Traumatic Stress Disorder (PTSD) market uptake by drugs; patient uptake by therapies; and sales of each drug.  

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Post-Traumatic Stress Disorder (PTSD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Post-Traumatic Stress Disorder (PTSD)'s key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for Post-Traumatic Stress Disorder (PTSD) emerging therapies.

Reimbursement Scenario in Post-Traumatic Stress Disorder (PTSD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Post-Traumatic Stress Disorder (PTSD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Post-Traumatic Stress Disorder (PTSD) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the Post-Traumatic Stress Disorder (PTSD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Post-Traumatic Stress Disorder (PTSD), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the Post-Traumatic Stress Disorder (PTSD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Post-Traumatic Stress Disorder (PTSD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Post-Traumatic Stress Disorder (PTSD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) market

Report Highlights

  • In the coming years, the Post-Traumatic Stress Disorder (PTSD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Post-Traumatic Stress Disorder (PTSD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
  • Major players are involved in developing therapies for Post-Traumatic Stress Disorder (PTSD). The launch of emerging therapies will significantly impact the Post-Traumatic Stress Disorder (PTSD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Post-Traumatic Stress Disorder (PTSD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Post-Traumatic Stress Disorder (PTSD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Post-Traumatic Stress Disorder (PTSD) Pipeline Analysis
  • Post-Traumatic Stress Disorder (PTSD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Post-Traumatic Stress Disorder (PTSD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Post-Traumatic Stress Disorder (PTSD) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Post-Traumatic Stress Disorder (PTSD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Post-Traumatic Stress Disorder (PTSD) drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Post-Traumatic Stress Disorder (PTSD) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings of the market across 7MM and which country will have the largest Post-Traumatic Stress Disorder (PTSD) market size during the forecast period (2019-2032)?
  • At what CAGR, the Post-Traumatic Stress Disorder (PTSD) market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Post-Traumatic Stress Disorder (PTSD) market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Post-Traumatic Stress Disorder (PTSD) market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of Post-Traumatic Stress Disorder (PTSD)?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Post-Traumatic Stress Disorder (PTSD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Post-Traumatic Stress Disorder (PTSD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about Post-Traumatic Stress Disorder (PTSD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Post-Traumatic Stress Disorder (PTSD) during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the Post-Traumatic Stress Disorder (PTSD) treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Post-Traumatic Stress Disorder (PTSD) in the USA, Europe, and Japan?
  • What are the Post-Traumatic Stress Disorder (PTSD) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Post-Traumatic Stress Disorder (PTSD)?
  • How many therapies are in-development by each company for Post-Traumatic Stress Disorder (PTSD) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Post-Traumatic Stress Disorder (PTSD) treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Post-Traumatic Stress Disorder (PTSD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Post-Traumatic Stress Disorder (PTSD) and its status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Post-Traumatic Stress Disorder (PTSD)?
  • What are the global historical and forecasted markets of Post-Traumatic Stress Disorder (PTSD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Post-Traumatic Stress Disorder (PTSD) market
  • To understand the future market competition in the Post-Traumatic Stress Disorder (PTSD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Post-Traumatic Stress Disorder (PTSD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Post-Traumatic Stress Disorder (PTSD) market
  • To understand the future market competition in the Post-Traumatic Stress Disorder (PTSD) market

1. Key Insights

2. Report Introduction

3. Post-Traumatic Stress Disorder Market Overview at a Glance

3.1. Market Share (%) Distribution of Post-Traumatic Stress Disorder in 2019

3.2. Market Share (%) Distribution of Post-Traumatic Stress Disorder in 2032

4. Executive Summary of Post-Traumatic Stress Disorder (PTSD)

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Causes of Post-Traumatic Stress Disorder

6.3. Risk Factors of Post-Traumatic Stress Disorder

6.4. Signs and Symptoms of Post-Traumatic Stress Disorder

6.5. Clinical Manifestations of Post-Traumatic Stress Disorders

6.6. Pathophysiology of Post-Traumatic Stress Disorder

6.7. Medications

6.8. Comorbidities of Post-Traumatic Stress Disorder

7. Diagnosis of Post-Traumatic Stress Disorder

7.1. Diagnostic Criteria

7.2. Diagnostic Algorithm of Post-traumatic disorder

7.3. The Differential Diagnosis of Post-Traumatic Stress Disorder

8. Treatment of Post-Traumatic Stress Disorder

8.1. Psychotherapy

8.2. Treatment Algorithm

9. Diagnosis and Treatment Guidelines

9.1. American Psychological Association

9.2. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-compulsive, and Post-Traumatic Stress Disorders

9.3. World Health Organization Guidelines for the Management of Conditions Specifically Related to PTSD 2013

9.4. NICE Guidelines for Post-Traumatic Stress Disorder (2018)

9.5. VA/DOD Clinical Practice Guideline for the Management of Post-Traumatic Stress Disorder and Acute Stress Disorder (2017)

10. Conclusion

11. Epidemiology and Patient Population

11.1. Key Findings

11.2. Epidemiology Scenario

11.2.1. Prevalence population of Post-Traumatic Stress Disorder

11.2.2. Diagnosed prevalent Cases of Post-Traumatic Stress Disorder

11.2.3. Gender-specific Cases of Post-Traumatic Stress Disorder

11.2.4. Severity-specific Cases of Post-Traumatic Stress Disorder

11.2.5. Age-specific Cases of Post-Traumatic Stress Disorder

11.2.6. Total Treated Cases of Post-Traumatic Stress Disorder

12. Patient Journey

13. Key Endpoints in Post-Traumatic Stress Disorder (PTSD) Clinical Trials

14. Emerging Therapies

14.1. Key cross competition- Emerging Therapies

14.2. JZP150: Jazz Pharmaceuticals

14.2.1. Product Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Developmental Activities

14.3. NYX-783: Aptinyx

14.3.1. Product Description

14.3.2. Other Developmental Activities

14.3.3. Clinical Developmental Activities

14.3.4. Safety and Efficacy

14.4. Rexulti (brexpiprazole) and Zoloft (sertraline) combination: Otsuka Pharmaceutical Development & Commercialization, Inc.

14.4.1. Product Description

14.4.2. Developmental activities

14.4.3. Clinical Developmental Activities

14.4.4. Safety and Efficacy

14.5. BNC210: Bionomics Limited

14.5.1. Product Description

14.5.2. Other Developmental Activities

14.5.3. Clinical Developmental Activities

14.5.4. Safety and Efficacy

15. Conjoint Analysis

16. Post-Traumatic Stress Disorder: 7 Major Market Analysis

16.1. Key Findings

17. Market Outlook

17.1. Market Size of Post-Traumatic Stress Disorder

17.1.1. Total Market Size of Post-Traumatic Stress Disorder

17.1.2. Market Size of Post-Traumatic Stress Disorder by Therapies

18. Market Access and Reimbursement

18.1. Key HTA decisions for PTSD

18.2. Patient Access Programs

19. KOL Views

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Unmet Needs

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

List of Table

Table 1: Prevalent Population Cases of Post-Traumatic Stress Disorder in Thousands (K)  (2019–2032)

Table 2: Diagnosed Prevalent Cases of Post-Traumatic Stress Disorder in thousands (K) (2019–2032)

Table 3: Gender-specific Cases of Post-Traumatic Stress Disorder (2019–2032)

Table 4: Severity-specific Cases of Post-Traumatic Stress Disorder (2019–2032)

Table 5: Age-specific Cases of Post-Traumatic Stress Disorder (2019–2032)

Table 6: Total Treated Cases of Post-Traumatic Stress Disorder (2019–2032)

Table 7: Comparison of emerging drugs under development

Table 8: JZP150, Clinical Trial Description, 2022

Table 9: NYX-783, Clinical Trial Description, 2022

Table 10: Brexpiprazole + sertraline, Clinical Trial Description, 2022

Table 11: BNC210, Clinical Trial Description, 2022

Table 12: 7MM Market Size of Post-Traumatic Stress Disorder in USD Million (2019–2032)

Table 13: 7MM Market Size of PTSD by Therapies in USD Million (2019–2032)

Table 14: Key HTA Decisions for PSTD

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Understanding of Post-Traumatic Stress Disorder

Figure 3: Causes of Post-Traumatic Stress Disorder

Figure 4: Risk factors of Post-Traumatic Stress Disorder

Figure 5: Signs and Symptoms of Post-Traumatic Stress Disorder

Figure 6: Pathophysiology of Post-Traumatic Stress Disorder

Figure 7: Treatment of Post-Traumatic Stress Disorder

Figure 8: Comorbidities of Post-Traumatic Stress Disorder

Figure 9: DSM-5 Diagnostic Criteria of Post-Traumatic Stress Disorder

Figure 10: Diagnostic Algorithm of Post-Traumatic Stress Disorder

Figure 11: Differential diagnosis of Post-Traumatic Stress Disorder

Figure 12: Timing of treatment of Post-Traumatic Stress Disorder

Figure 13: Treatment Algorithm of Post-Traumatic Stress Disorder

Figure 14: Prevalent Population of Post-Traumatic Stress Disorder in the 7MM (2019–2032)

Figure 15: Diagnosed Prevalent Cases of Post-Traumatic Stress Disorder in the 7MM (2019–2032)

Figure 16: Gender-specific Cases of Post-Traumatic Stress Disorder In the 7MM (2019–2032)

Figure 17: Severity-specific Cases of Post-Traumatic Stress Disorder in the 7MM (2019–2032)

Figure 18: Age-specific Cases of Post-Traumatic Stress Disorder in the 7MM (2019–2032)

Figure 19: Total Treated Cases of Post-Traumatic Stress Disorder in the 7MM (2019–2032)

Figure 20: Market Size of Post-Traumatic Stress Disorder in the 7MM in USD Million (2019–2032)

Figure 21: 7MMMarket Size of Post-Traumatic Stress Disorder (PTSD) by Therapies in USD Million (2019–2032)

Jazz Pharmaceuticals
Aptinyx
Otsuka Pharmaceutical Development & Commercialization, Inc.
Bionomics Limited

 

Forward to Friend

Need A Quote